Proteome, Agilent to partner for glycomics applications, software development

By Elaine Rigoli

Tampa, Fla., Aug. 3 - Proteome Systems Ltd. and Agilent Technologies, Inc. announced the expansion of their cooperative marketing agreement to develop new solutions for the discovery of diagnostic markers and drug targets by glycomics analysis.

Glycomics is the study of the structure and functions of sugar. Many diseases, such as cancer, arthritis and influenza, cause changes to the sugars that are attached to proteins.

The companies said these changes in sugars can serve as powerful diagnostic biomarkers of the diseases.

Agilent is a technology measurement company based in Palo Alto, Calif.

Proteome is a biotechnology company based in Sydney, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.